Xcout IntelGenSight Biologics
GenSight Biologics is a clinical-stage biopharmaceutical company that develops gene therapies to treat neurodegenerative retinal diseases and central nervous system disorders. The company focuses on addressing conditions such as Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa, and Geographic Atrophy using technologies like gene therapy, mitochondrial targeting sequences, and optogenetics.
Subscribe to see GenSight Biologics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
GenSight Biologics at a glance
GenSight Biologics is a biotech company headquartered in France, founded in 2012. Xcout tracks 14 named people at GenSight Biologics, including Laurence Rodriguez (Chief Executive Officer).
GenSight Biologics leadership
- Laurence RodriguezChief Executive Officer
- Jan Eryk UmiastowskiChief Financial Officer
- Marion GhibaudoChief Technical Officer Medical Device
- Scott JeffersChief Technical Officer
- Li FangChief Regulatory & Quality Officer
- Magali TaielChief Medical Officer
8 more named people on record for GenSight Biologics, with roles, board committees and tenure — see the full roster →
GenSight Biologics competitors
A few of GenSight Biologics's closest competitors — see the full list of competitors and alternatives →
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Ray Therapeutics, Inc. is a privately held optogenetic gene therapy company headquartered in Berkeley, California. The company focuses on reimagining vision through innovative genetic treatments and novel therapeutic solutions.
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Get GenSight Biologics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on GenSight Biologics in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access